Skip to content
N1 Life
All Insights

Research & Industry

Delgocitinib Cream Gains Approval in China for Chronic Hand Eczema

China has approved delgocitinib cream for eligible adults with moderate-to-severe chronic hand eczema.

  • chronic hand eczema
  • topical JAK inhibitor
  • clinical evidence

A new topical option for chronic hand eczema

On November 13, 2026, LEO Pharma announced that China’s National Medical Products Administration had approved delgocitinib cream for adults with moderate-to-severe chronic hand eczema when topical corticosteroids are inadequate or inappropriate. The approval adds a non-steroidal topical option for a condition that can disrupt work and everyday activities. [1]

Chronic hand eczema can involve itching, pain, scaling and fissures. It is generally defined by symptoms lasting more than three months or recurring at least twice in a year. Frequent exposure to water or irritants can add to the challenge of managing affected hands in daily life. [1]

What DELTA China measured

Delgocitinib is a topical pan-Janus kinase (JAK) inhibitor. The approval was supported by the phase 3 DELTA China trial and the wider delgocitinib clinical program. DELTA China compared twice-daily delgocitinib cream with vehicle over a 16-week double-blind period. The study enrolled 362 Chinese adults and adolescents aged 12 or older; the China approval announced by LEO applies to adults. [1, 2]

The primary endpoint was treatment success on the investigator’s global assessment at week 16: clear or almost clear skin, with an improvement of at least two grades from baseline. LEO reported a statistically significant benefit over vehicle. The company announcement did not give the group percentages for that endpoint. [1, 2]

Two earlier international phase 3 trials, DELTA 1 and DELTA 2, used the same treatment-success definition. At week 16, the respective proportions were 19.7% and 29.1% with delgocitinib, compared with 9.9% and 6.9% with vehicle. These figures describe the international studies, not DELTA China. [3]

A formulation used where life happens

Hands are washed, exposed and used throughout the day. That makes a topical treatment’s formulation and use schedule part of the experience of living with chronic hand eczema. For developers, clinical endpoints sit alongside practical questions about application, tolerability and sustained use.

The approval provides an example of a targeted anti-inflammatory medicine developed in a topical form for a defined patient population. It also expands the evidence available to teams considering how local treatment can fit a particular disease and site of application.

Sources

  1. LEO Pharma. NMPA approval of delgocitinib cream for chronic hand eczema in China. November 13, 2026.
  2. ClinicalTrials.gov. DELTA China, NCT06004050.
  3. Bissonnette R, et al. DELTA 1 and DELTA 2 phase 3 trials. The Lancet. 2024.
  4. N1 Life. LEO Pharma:外用泛JAK抑制剂德戈替尼乳膏在华获批. WeChat, November 17, 2026.